Faron Pharmaceuticals Ltd. on April 14 announced positive topline results of the BEXMAB trial, which shows a high overall response rate among both frontline as well as relapsed/refractory high-risk myelodysplastic syndromes patients treated with a combination of bexmarilimab and azacitidine.
To access this subscriber-only content please log in or subscribe.
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe